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Available online 23 April 2018Background: Hypoxia is associated with a poor prognosis in prostate cancer. This work aimed to derive and val-
idate a hypoxia-related mRNA signature for localized prostate cancer.
Method: Hypoxia genes were identiﬁed in vitro via RNA-sequencing and combined with in vivo gene co-expres-
sion analysis to generate a signature. The signature was independently validated in eleven prostate cancer co-
horts and a bladder cancer phase III randomized trial of radiotherapy alone or with carbogen and nicotinamide
(CON).
Results: A 28-gene signature was derived. Patients with high signature scores had poorer biochemical re-
currence free survivals in six of eight independent cohorts of prostatectomy-treated patients (Log rank
test P b .05), with borderline signiﬁcances achieved in the other two (P b .1). The signature also predicted
biochemical recurrence in patients receiving post-prostatectomy radiotherapy (n = 130, P = .007) or
deﬁnitive radiotherapy alone (n = 248, P = .035). Lastly, the signature predicted metastasis events in
a pooled cohort (n = 631, P = .002). Prognostic signiﬁcance remained after adjusting for clinic-patho-
logical factors and commercially available prognostic signatures. The signature predicted beneﬁt
from hypoxia-modifying therapy in bladder cancer patients (intervention-by-signature interaction test
P = .0026), where carbogen and nicotinamide was associated with improved survival only in hypoxic tu-
mours.Keywords:
Gene expression signature
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Prostate cancer
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Ninety percent of prostate cancer (PCa) patients are diagnosed with
localized carcinoma, which have a highly variable course of disease pro-
gression. Hypoxia is a common micro-environmental feature in most
solid tumours, which leads to changes in transcriptomic proﬁles, a
higher potential tometastasise and resistance to radiotherapy [1]. Local-
ized prostate cancer has marked and heterogeneous hypoxia [2], and
hypoxia is an adverse prognostic feature [3–5]. Combining hypoxia-
targeting treatmentwith radiotherapywas shown to improve local con-
trol of tumours and survival of patients in head and neck and bladder
cancers [6–9]. There is good evidence from the literature that the most
hypoxic tumours beneﬁt the most from hypoxia-modifying therapy.
However, there is no clinically validated method of selecting prostate
cancer patients who would beneﬁt from hypoxia modifying treatment.
Hypoxia gene signatures were successfully derived for multiple tu-
mour sites including head and neck, bladder, soft tissue sarcoma and
cervical cancers, which were not only independently prognostic but
also predictive of beneﬁt from hypoxia-modifying therapy in head and
neck and bladder cancers [10–18]. Work in prostate cancer showed
some prognostic signiﬁcance for signatures derived in other tumour
types [3] or associated with the hypoxia marker pimonidazole [15].
We previously showed that hypoxia gene signatures are better if tu-
mour site speciﬁc [19]. The aim of this study was to generate and vali-
date a prostate cancer-speciﬁc transcriptomic signature. In vitro
analysis of genes regulated by hypoxia was combined with in vivo anal-
ysis of a gene co-expression network and patient survival using data
from a retrospective cohort. Following signature derivation, validation
was performed in multiple independent cohorts.
2. Methods
2.1. Patient Cohorts
This study included patients with prostate carcinoma from twelve
cohorts, including the cancer genome atlas project (TCGA) [20],
GSE54460 [21], GSE21032 [22], CPC-GENE [23], Cambridge [24,25], six
retrieved from the Decipher GRID™ prostate cancer database
(NCT02609269) [26–31], and one from Belfast [32]. A summary of the
cohorts and procedures for pre-processing of transcriptomic data are
provided in Supplementary Table 1 and Supplementary Methods. Pa-
tient cohort characteristics are summarised in Supplementary Table 2.
The TCGA cohort was used as the training cohort. In addition, bladder
cancer patients enrolled in a randomized trial of hypoxia-modifying
therapy were available in the BCON cohort [6,18]. Informed consent
protocols were approved by local Institutional Review Boards.
2.2. Endpoints and Statistical Analysis
Biochemical recurrence (BCR) free survivalwas the clinical endpoint
of this study in all but one cohort. Distant metastasis (DMET) free sur-
vival was the clinical endpoint of the other cohort. Patient follow up
data were censored at 5-year. The signature derived from this work
assigned one hypoxia signature score for each individual tumour and
in each cohort patients were stratiﬁed into high vs. low hypoxia based
on the median cohort signature score. Survival estimates were per-
formed using the Kaplan-Meier method. The Log-rank test was used
to test the null hypothesis of equality of survival distributions. Hazard
ratios (HR) and 95% conﬁdence intervals (CI) were obtained using theCox proportional hazard model. In case-cohort studies (originally de-
signed to sample the adverse pathology population to estimate risk of
metastasis after radical prostatectomy), randomly sampled sub-cohorts
were used in order to reduce over-estimation of events in evaluation of
the BCR endpoint. Odds ratios (OR) were obtained using logistic regres-
sion models. Association between hypoxia signature score and Gleason
group, tumour stagewas estimated using simple linear regression. All P-
values were two sided and statistical signiﬁcance was set as 0.05.
2.3. Prostate Cancer Hypoxia Signature Development
A network-basedmethodologywas applied for generation of a pros-
tate cancer-speciﬁc hypoxia signature, hypothesising that in vitro hyp-
oxia regulated genes co-expressing with each other in vivo collectively
indicate tumour hypoxia. Brieﬂy, genes up- and down-regulated by
hypoxia (1% O2, 24 h) were identiﬁed with RNA sequencing in four
PCa cell lines (PNT2-C2, LNCaP, DU-145, and PC-3). The four cell lines
were chosen as they were derived from human tissues and are widely
used as in vitro PCamodels [33]. A gene co-expression networkwas con-
structed in a TCGA training cohort and a putative genemodule enriched
with in vitro hypoxia genes was identiﬁed. Genes within the putative
module were ranked by their connectivity and added iteratively into
the signature. The ﬁnal signature was selected based on prognostic sig-
niﬁcance. The signature scores are a continuous variable, which were
then binarised into high and low categories using the median value
for each cohort. The hypoxia signature derived here was then indepen-
dently validated in the other eleven PCa cohorts. In multivariable anal-
ysis, the hypoxia gene signature was adjusted for standard clinic-
pathological factors and a genomic classiﬁer Decipher [27]. More details
were given in Supplementary Methods.
2.4. Comparison with Literature Transcriptomic and Genomic Signatures
Seven hypoxia [10,11,14–17] and eleven prostate cancer
transcriptomic signatures [34–44]were curated from the literature and
their prognostic signiﬁcances were evaluated for comparison (Supple-
mentary methods). Furthermore, the potential beneﬁt of combining
the de novo hypoxia signature with a prognostic 31-loci DNA classiﬁer
[45] was also investigated by entering both into a Cox model.
3. Results
3.1. In Vitro Hypoxia Responsive Genes
Genes up or down regulated under hypoxia in four PCa cell lines
were identiﬁed. 84, 306 and 848 genes were differentially expressed
in greater than four, three and two cell lines, respectively. A seed gene
database was constructed consisting of the 848 genes differentially
expressed in two or more cell lines (Supplementary Table 3). Eight
cell cycle and metabolism pathways were enriched in the hypoxia
seed genedataset (Supplementary Table 4). Formany of the above iden-
tiﬁed genes, their regulation under hypoxia was well documented
[46,47].
3.2. In Vivo Prostate Cancer-speciﬁc Hypoxia Gene Module
A PCa gene co-expression networkwas built from pre-treatment tu-
mour biopsies in the TCGA cohort. The network, containing 1856 genes
(including 113 seed genes) of good variability was partitioned into 34
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lated as 33% of its member genes (22/66, P=4.85 ∗ 10−12, Supplemen-
tary Fig. 1) were seed genes. Another 24 genes from the 66-gene
module were hypoxia regulated in one cell line (Supplementary Fig.
2). The ﬁnal signature, containing 28 genes from the 66-gene module,
was derived by evaluating prognostic signiﬁcance in cross validation.
The signature gene coefﬁcients were determined from a Cox survival
model (Supplementary Table 5). Patients with high signature scoresFig. 1. Kaplan-Meier or receiver operating characteristic plots for independent vawere associated with signiﬁcantly poorer outcome (log rank P=1.9 ∗
10−8, Supplementary Fig. 3).
3.3. 28-Gene Signature Is Prognostic of BCR in PCa Cohorts Receiving Radi-
cal Prostatectomy
Thehigh correlation among the 28hypoxia signature geneswaswell
preserved in the independent validation cohorts (Supplementary Fig.lidation of the 28-gene hypoxia signature in prostatectomy-treated cohorts.
Table 1
Multivariable analysis of the 28-gene hypoxia signature in independent cohorts of PCa pa-
tients receiving radical prostatectomy.
Study Variable Multivariable analysis
Cohort and case-cohort studies HR (95% CI) P-value
GSE21032 Hypoxia 3.51 (1.21–10.15) 0.021
Gleason Group 2 VS 1 0.69 (0.20–2.47) 0.57
Gleason Group 3 VS 1 4.12 (1.32–12.91) 0.015
Gleason Group ≥ 4 VS 1 2.45 (0.72–8.31) 0.15
Log2 pre-treatment PSA 1.04 (0.64–1.69) 0.88
SVI 3.86 (1.25–11.92) 0.019
SM 1.44 (0.55–3.74) 0.46
ECE 2.58 (0.70–9.52) 0.155
GSE54460 Hypoxia 1.84 (1.00–3.39) 0.048
Gleason Group 2 VS 1 1.49 (0.42–5.34) 0.54
Gleason Group 3 VS 1 2.77 (0.76–10.13) 0.123
Gleason Group 4 VS 1 2.21 (0.45–10.74) 0.33
Gleason Group 5 VS 1 2.33 (0.50–10.83) 0.28
Log2 pre-treatment PSA 1.74 (1.21–2.50) 0.0029
Clinical T Stage 2 VS 1 0.47 (0.22–1.01) 0.052
Clinical T Stage ≥ 3 VS 1 0.62 (0.23–1.62) 0.33
SM 2.47 (1.35–4.55) 0.0035
Cambridge Hypoxia 1.53 (0.54–4.30) 0.42
Gleason Group 2 VS 1 1.84 (0.20–17.28) 0.59
Gleason Group 3 VS 1 8.27 (0.79–86.99) 0.078
Gleason Group 4 VS 1 15.66 (1.36–181.00) 0.028
Gleason Group 5 VS 1 490.3 (11.7–20,542.2) 0.0011
Log2 pre-treatment PSA 0.54 (0.22–1.37) 0.19
SM 1.32 (0.46–3.76) 0.61
ECE 1.42 (0.42–4.72) 0.57
CPC-GENE Hypoxia 1.81 (1.02–3.21) 0.021
Gleason Group 2 VS 1 0.85 (0.35–2.05) 0.68
Gleason Group 3 VS 1 0.82 (0.31–2.20) 0.65
Gleason Group ≥ 4 VS 1 3.00 (0.27–33.85) 0.310
Pre-treatment PSA 1.04 (0.98–1.11) 0.152
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ture genes also clustered tumours in independent validation cohorts
into two clear groups (Supplementary Figs. 5 and 6).
The 28-gene signature and all coefﬁcients were frozen and applied
to independent validation cohorts. The prognostic value of the 28-
gene hypoxia signature was ﬁrst validated in the GSE21032 (fresh fro-
zen), GSE54460 (FFPE) and Cambridge (fresh frozen) prostatectomy co-
horts. In both GSE21032 and GSE54460, tumours with high 28-gene
signature scores were associated with signiﬁcantly poorer 5-year BCR
in the GSE21032 (n=131, HR 4.59, 95% CI 1.71–12.32, P= .0025, Fig.
1A) and GSE54460 (n= 106, HR 2.12, 95% CI 1.20–3.74, P= .0098,
Fig. 1B) cohorts. In the Cambridge cohort, borderline prognostic signiﬁ-
cance was observed with the default median cut-off signature score (n
= 111, HR 2.54, 95% CI 0.96–6.69, P= .06, Fig. 1C), which improved
when an upper quartile split was used (HR 4.54, 95% CI 1.82–11.36, P
= .0011). A continuous 28-gene signature score also achieved prognos-
tic signiﬁcance (P= .047) in the Cambridge cohort.
In other ﬁve prostatectomy-treated cohorts, tumours with high 28-
gene signature scores were again associated with signiﬁcantly poorer
outcome (GSE79957: n=260, HR 1.60, P= .055; GSE62116: n=235,
HR 2.04 P= .007; GSE41408: n= 48, OR 7.60, P= .0022; GSE62667:
n= 182, OR 5.90, P= .000036; and CPC-GENE: n= 212, HR 1.80, P
= .026. Fig. 1D to H).
Multivariable analysis was performed adjusting the hypoxia signa-
ture with clinicopathological covariates and the Decipher genomic clas-
siﬁer, wherever possible (Table 1). Statistical signiﬁcance was retained
in three cohorts (GSE21032: HR 3.51, P= .021; GSE54460: HR 1.84, P
= .048; and CPC-GENE: HR 1.81, P= .021), and was borderline in an-
other two cohorts (GSE62116: HR 1.36, P= .059; and GSE41408: OR
2.89, P= .081).Clinical T Stage 2 VS 1 1.80 (1.03–3.13) 0.018
GSE62116 Hypoxia 1.36 (0.99–1.88) 0.059
Decipher 1.15 (0.86–1.53) 0.36
Gleason Group 3 VS ≤ 2 2.21 (1.10–4.40) 0.026
Gleason Group 4 VS ≤ 2 1.29 (0.57–2.93) 0.54
Gleason Group 5 VS ≤ 2 1.13 (0.53–2.44) 0.75
Log2 pre-treatment PSA 1.21 (0.96–1.52) 0.10
SVI 0.87 (0.46–1.66) 0.68
SM 1.67 (0.95–2.95) 0.076
ECE 1.83 (1.01–3.31) 0.046
LNI 0.73 (0.31–1.74) 0.48
GSE79957 Hypoxia 0.93 (0.58–1.48) 0.76
Decipher 1.58 (1.11–2.23) 0.010
Gleason Group 3 VS ≤ 2 0.84 (0.33–2.17) 0.72
Gleason Group 4 VS ≤ 2 1.32 (0.46–3.82) 0.61
Gleason Group 5 VS ≤ 2 2.46 (1.20–5.03) 0.014
Log2 pre-treatment PSA 1.25 (0.94–1.66) 0.122
SVI 1.57 (0.82–3.03) 0.1803.4. 28-Gene Signature is a Strong Independent Prognostic Factor in PCa Co-
horts Receiving Radiotherapy
The 28-gene signature predicted biochemical recurrence in the
GSE72291 cohort treated with post-operative radiotherapy (n= 130,
HR 2.81, 95% CI 1.33–6.00, P= .007, Fig. 2A). In multivariable analysis
(Table 2), the hypoxia signature remained a strong prognostic factor
(HR = 2.17, P= .014) alongside Decipher (HR 2.24, P= .0061),
Gleason group 5 (HR 8.50, P= .0012), and pre-treatment PSA level
(HR 1.74, P= .0042). The hypoxia signature was also prognostic in
the Belfast cohort of intermediate/high-risk patients who underwent
deﬁnitive radiotherapy (n=248, log rank P= .035, Fig. 2B). Multivari-
able analysis was not performed due to the low event rate.SM 1.96 (0.99–3.88) 0.052
ECE 2.18 (0.85–5.60) 0.104
LNI 4.71 (2.43–9.14) b0.001
Case control studies OR (95% CI) P-value
GSE62667 Hypoxia 1.19 (0.62–2.30) 0.61
Decipher 2.26 (1.28–4.23) 0.0069
Gleason Group 3 VS ≤ 2 1.77 (0.47–6.38) 0.39
Gleason Group 4 VS ≤ 2 2.03 (0.43–8.98) 0.36
Gleason Group 5 VS ≤ 2 8.68 (1.94–42.91) 0.0057
Log2 pre-treatment PSA 1.56 (0.97–2.57) 0.071
SVI 2.70 (0.81–8.99) 0.1033.5. 28-Gene Signature Predicts Metastatic Outcome
The 28-gene signature was also evaluated in a pooled cohort of 631
PCa patients from four studies withmetastatic outcome [29–31,48]. The
signature predicted distant metastasis events with a HR of 2.41 (95% CI
1.38–4.19, P= .002). In multivariable analysis, the hypoxia signature
remained signiﬁcant (HR 2.57, 95% CI 1.38–4.77, P= .003) alongside
Decipher, seminal vesicle invasion and lymph node invasion (Table 3).SM 2.20 (0.80–6.39) 0.133
ECE 3.99 (1.01–20.55) 0.067
GSE41408 Hypoxia 2.89 (0.94–10.79) 0.081
Decipher 0.41 (0.089–1.66) 0.22
Gleason Group 3 VS ≤ 2 1 (0-NA) 0.99
Gleason Group ≥ 4 VS ≤ 2 3.94 (0.29–67.75) 0.31
Log2 pre-treatment PSA 3.02 (1.29–9.55) 0.031
PSA: prostate speciﬁc antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE:
extracapsular extension; LNI: lymph node invasion.3.6. 28-Gene Signature Is AssociatedWith Gleason Score and Tumour Stage
A positive and signiﬁcant correlation was seen between the 28-gene
signature score and pathological Gleason score in ﬁve of the six exam-
ined cohorts (Supplementary Fig. 7). Hypoxia score increased signiﬁ-
cantly with tumour stage in four of the six cohorts (Supplementary
Fig. 8), but was not associated with pre-treatment PSA (Supplementary
Fig. 9). In GSE21032, the hypoxia signature scores were signiﬁcantly
higher in metastatic compared with primary tissue (P= .007, Supple-
mentary Fig. 10).
Fig. 2. Kaplan-Meier plots for independent validation of the 28-gene hypoxia signature in A) post-prostatectomy radiotherapy cohort; B) radiotherapy-treated cohort.
186 L. Yang et al. / EBioMedicine 31 (2018) 182–1893.7. Prediction of Beneﬁt from Hypoxia Modiﬁcation of Radiotherapy
The 28-gene prostate signature was further validated in the BCON
phase III randomized trial of radiotherapy alone or with carbogen and
nicotinamide (CON) for bladder cancer patients. Tumours were strati-
ﬁed as high or low from median, ﬁrst, and third quartiles of cohort 28-
gene signature scores. When the ﬁrst quartile was used, high hypoxic
tumours were associatedwith a non-signiﬁcant trend of poor prognosis
in patients treated with radiotherapy only (overall survival, n=75, HR
1.68, P= .17, Supplementary Fig. 11). BCON tumours stratiﬁed as high
hypoxic had improved survival with the addition of CON (n=113, HR
0.54, 95% CI 0.32–0.91, P= .021). For low-hypoxic tumours, giving
CON with RT was associated with poorer survival (n= 38, HR 2.49,
95% CI 1.06–5.89, P= .037, Supplementary Fig. 12). A signature-inter-
vention interaction test conﬁrmed the predictive value of the signature
for both binary hypoxic status (P= .0026) and continuous hypoxia
score (P= .037). CON was shown to have a detrimental effect on the
25% BCON patients with low 28-gene signature scores. As one given
treatment would only beneﬁt a subset of patients and might even pro-
duce adverse effect on others, this emphasized the importance of iden-
tifying reliable predictive biomarker.Table 33.8. Comparison with Literature Gene Signatures
The prognostic value of published hypoxia and PCa transcriptomic
signatures were compared in both GSE21032 and GSE54460 (Supple-
mentary Tables 6 and 7). One PCa hypoxia signature [15] reachedTable 2
Multivariable analysis of the 28-gene signature in predicting biochemical recurrence in
patients receiving radical prostatectomy and adjuvant radiotherapy.
Study Variable Multivariable analysis
GSE72291 Hypoxia 2.17 (1.17–4.01) 0.014
Decipher 2.24 (1.26–4.00) 0.0061
Gleason Group 3 VS ≤ 2 2.49 (0.72–8.56) 0.148
Gleason Group 4 VS ≤ 2 2.34 (0.67–8.21) 0.183
Gleason Group 5 VS ≤ 2 8.50 (2.34–30.92) 0.0012
Log2 pre-treatment PSA 1.74 (1.19–2.55) 0.0042
SVI 1.21 (0.51–2.85) 0.66
SM 0.60 (0.25–1.49) 0.27
ECE 3.15 (0.89–11.17) 0.075
PSA: prostate speciﬁc antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE:
extracapsular extension; LNI: lymph node invasion.(borderline) prognostic signiﬁcance in both cohorts. The Toustrup sig-
nature [16], derived for head and neck cancer, was prognostic in both
cohorts. Our 28-gene signature scores correlated moderately with
Toustrup signature scores (GSE21032: Pearson r= 0.33, P= .00011;
GSE54460: Pearson r=0.51, P=2.32 ∗ 10−8, Supplementary Fig. 13).
The 28-gene signature had higher prognostic signiﬁcance and was the
only signiﬁcant factor when both signatures were entered into a Cox
proportional hazards regression model (Supplementary Table 8).
3.9. Association with Copy Number Alteration Burden and Genomic
Classiﬁer
Recent studies suggested global copy number alteration (CNA) bur-
den as a prognosticmarker of PCa patients [22,49]. A verymoderate cor-
relation was found between global CNA burden, deﬁned as the
percentage of the tumour genome affected by CNA, and hypoxia signa-
ture scores for both TCGA (Pearson correlation 0.36, Supplementary Fig.
14) and GSE21032 (Pearson correlation 0.40, Supplementary Fig. 14).
Hypoxia signature (binary or continuous) and CNA burden (continu-
ous) both retained signiﬁcance when entered together into a Cox
model in both cohorts (Supplementary Tables 9 and 10).
A 100-loci prognostic classiﬁer for localized PCa [3] was recently
identiﬁed and reduced to a 31-loci signature [45]. Both reﬂect genomic
instability and were shown to have high prognostic value in N500 pros-
tate cancer patients. We examined if adding the 28-gene signature and
genomic classiﬁer could further improve prognostication for PCaMultivariable analysis of the 28-gene signature in predicting metastatic outcome.
Study Variable Multivariable analysis
Pooled cohort Hypoxia 2.57 (1.38–4.77) 0.003
Decipher 1.22 (1.06–1.41) 0.007
Gleason Group 2 VS 1 1.13 (0.14–9.30) 0.907
Gleason Group 3 VS 1 3.50 (0.43–28.26) 0.239
Gleason Group 4 VS 1 3.67 (0.45–30.06) 0.226
Gleason Group 5 VS 1 5.83 (0.74–45.96) 0.094
Log2 pre-treatment PSA 1.02 (0.79–1.33) 0.864
AGE 0.99 (0.95–1.03) 0.522
SVI 2.01 (1.15–3.51) 0.014
SM 1.45 (0.84–2.51) 0.18
ECE 1.39 (0.70–2.75) 0.346
LNI 1.95 (1.04–3.67) 0.037
PSA: prostate speciﬁc antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE:
extracapsular extension; LNI: lymph node invasion.
187L. Yang et al. / EBioMedicine 31 (2018) 182–189patients. In the CPC-GENE cohort [23], the 28-gene signature (log rank
P= .023, Fig. 1F) achieved similar prognostic signiﬁcance compared
with the 31-loci genomic instability classiﬁer (log rank P= .042, Sup-
plementary Fig. 15). Combining the 31-loci genomic classiﬁer with the
28-gene signature improved prognostication (log rank P= .0035, Sup-
plementary Fig. 16). Using patients with low 28-gene signature and
low 31-loci signature as a reference, patients with high 28-gene signa-
ture and high 31-loci signature had a signiﬁcantly poorer outcome
(HR 2.75, 95% CI 1.42–5.31, P= .0026). Patients with only positive 28-
gene signature (P= .58) or 31-loci signature (P= .41) had similar sur-
vival as the double negative group, respectively (Supplementary Table
11). The above analyses suggested that improved prognostication can
be achieved by combining the 28-gene signature and indicators of ge-
nome instability, consistentwith the previous observation from Lalonde
et al. [3].
4. Discussion
A 28-gene signature was derived and shown to be independently
prognostic in eleven cohorts of low- to high-risk prostate cancer pa-
tients with localized disease. Ten genes (ATF3, BHLHE40, SLC2A3, EGR1,
KLF10, FOSL2, CYR61, SLC2A14, KLF6, and TIPARP) in the 28-gene signa-
turewere previously shown to be hypoxia regulated in different tumour
sites (Supplementary Table 12). The study showed that the Toustrup
hypoxia signature [16], prognostic and predictive of hypoxia-modifying
therapy for head and neck cancer, was prognostic in prostate cancer pa-
tients. The Ragnum signature [15], the only prostate cancer-speciﬁc
hypoxia signature in the literature, had (borderline) prognostic signiﬁ-
cance for biochemical recurrence. Amoderate correlationwas found be-
tween the Toustrup 15-gene and our 28-gene hypoxia signatures score.
The derived 28-gene signature could be combined with a recently pub-
lished genomic classiﬁer to identify a group of high-risk PCa patients
with very poor prognosis. The 28-gene hypoxia signature has transla-
tional signiﬁcance. The prognostic value of the signature was indepen-
dently validated in seven cohorts of biopsies preserved in FFPE blocks,
a routine technique for preserving tissues in hospitals. Degradation
and chemical modiﬁcation of nucleic acids in FFPE samples signiﬁcantly
reduces RNA quality. [50] The prognostic signiﬁcance of the signature
was also conﬁrmed using three major high-throughput expression pro-
ﬁling platforms, i.e. Affymetrix array, Illumina BeadArray and RNA-seq.
The results of the current study clearly indicate the robustness of the
signature for routine clinical application.
Onemajor limitation for the derived 28-gene signature is the lack of
benchmarking against gold-standard hypoxia measurement with
polographic needle oxygen electrodes. Prognostic information was
used in the signature derivation procedure, therefore the ﬁnal signature
could reﬂect other poor prognostic parameters beyond hypoxia. Use of
needle electrode presents great technical challenge, where to date the
Toustrup [16] is the only gene expression biomarker that reﬂected oxy-
gen partial pressure in human tissue. Ragum [15] derived a prostate
hypoxia signature based on pimonidazole staining, another approach
for assessing tumour hypoxia.
In this study, 1% oxygen concentrationwas chosen for in vitro exper-
iment as it is widely used in the literature and protein expression of HIF,
a major regulator of transcriptional responses to hypoxia, stabilizes in
cell lines around this oxygen concentration. One limitation is that cer-
tain transcriptional program, for example unfolded protein response
genes [51] which are generally activated in oxygen level ≤ 0.2%, might
be missed. Furthermore, previous research suggested that prostate tu-
mours were profoundly hypoxic with a median oxygen concentration
of ~0.5% [52]. Therefore, the signature derived here could be further re-
ﬁned in future studies by adding genes regulated at even lower oxygen
concentration.
Another limitation is that the 28-gene signature was prospectively
validated in retrospective cohorts, where no standardisation could be
achieved in terms of tissue handling, RNA extraction, the amount oftumour material, etc. However, the prognostic signiﬁcance was clearly
validated, showing a good level of signature robustness. Other limita-
tions include the inability to validate the signature in a prostate cancer
phase III trial involving hypoxiamodiﬁcationwith both gene expression
data and patient outcome. The 28-gene prostate signature was predic-
tive of hypoxia modiﬁcation therapy for bladder cancer – the only hyp-
oxia modiﬁcation trial available with full gene expression data. Use of a
median score as a cut-off might not be optimal but was chosen as a pre-
determined threshold to avoid bias and to provide balanced groups.
Also, a median cut-off was used for our head and neck and bladder sig-
natures. Different thresholdswere used for different hypoxia signatures
and arrays [16,53], and there is no consensus on the idealmethod to de-
ﬁne tumours as hypoxic and no methodological study exists to date
assessing and comparing the performance of the different methods. In
a prospective clinical trial the ﬁrst ~50 patient samples could be used
to generate a median threshold in newer FFPE blocks for classiﬁcation.
The 28-gene signature might be further reduced while achieving
comparable or slightly worse but acceptable prognostic value. Iden-
tifying the minimum set of genes for a signature is a very open re-
search problem. The enormous number of unique combinations of
28 genes deﬁnitely opens the door for potential reduction of the
signature.
In conclusion, a hypoxia gene signature for primary prostate tu-
mours was derived. Employed as a potential tool for personalized med-
icine, the signature identiﬁes that more hypoxic tumours have poorer
outcome. The signature warrants ﬁnal qualiﬁcation in a prospective
28-gene signature-driven randomized trial of hypoxia-modifying
therapy.
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